SUMMARY Eight patients with chronic Q fever endocarditis were treated with tetracycline for up to 40 months. In addition, five of these patients received co-trimoxazole. Six patients had prosthetic valves. Two patients who had Q fever endocarditis on their native valves required valve replacement because of haemodynamic difficulties: in only one did the Q fever endocarditis contribute to the haemodynamic difficulty. One patient died.
Q fever was first recognised as a clinical entity by Derrick Clinically acute Q fever may present as an atypical pneumonia or as a febrile illness which lasts two to three weeks. However, Q fever also exists in a chronic form, and endocarditis is a feature of the chronic disease.
This report describes the management of chronic Q fever endocarditis in eight patients. Six 7 December 1979 of Northern Ireland. There were five men and three women, aged between 24 and 67 years (Table  1) . Their occupations were farmer, farmer's wife, farm-feed salesman, housewife, labourer, two factory workers, and a civil servant. All the patients were either in contact with cattle or sheep or had drunk unpasteurised milk.
All patients had rheumatic valve disease. Six of the eight patients had previous heart surgery, where the valves had been replaced by prosthetic valves (Table 1 ). All valves removed at the time of operation were studied microscopically and showed no evidence of microbial infection.
Sera from the patients were tested against Q fever phase 1 and phase 2, psittacosis-lymphogranuloma venereum, and yolk sac antigens using the complement fixation technique as described by Bradstreet and Taylor3 and the microtitre system. All antibody titres were expressed as reciprocals of Table 2 Haematological data   Case no.   1  2  3  4  5  6  7  8 Hb (g)   9-5  120  7-8  8-7  13-3  140  145  103  ESR  42  72  60  150  61  14  5  125  Platelets   -28 000  22 000  62 000  200 000  125 000  180 000  260 000  Gamma globulin   18 0  22-0  28-0  36-0  28-0  24-0  -30 0  IgG  16 antibody titre of 640 he had the clinical manifestations of endocarditis. Six patients were treated medically and two had a combination of medical and surgical treatment (Table 3 ). All were started on tetracycline 2 g/day. Five patients were also given co-trimoxazole (trimethoprim 320 mg and sulphamethoxazole 1600 mg/day). During treatment the Q fever phase 1 and phase 2 antibody titres were monitored. Case 1 stopped co-trimoxazole after two-and-a-halfmonths. Case 2 had co-trimoxazole for one week and then developed a rash which necessitated the drug's withdrawal. In one patient (case 5) tetracycline was discontinued after six months since no significant reduction in phase 1 and phase 2 antibody titres had occurred. Co-trimoxazole was then started and after two months of treatment a significant reduction in phase 1 antibody titre occurred. The remaining two patients (cases 4 and 7) have received tetracycline and co-trimoxazole for 24 and seven months, respectively, and continue with the treatment without side effects.
With the exception of case 3 who died after 23 days and case 7 who has been o;n treatment for seven months, the other six patients have shown a significant reduction in Q fever phase 1 and phase 2 antibody titres.
Of the surgically treated patients, case 1 had chronic Q fever endocarditis in association with severe mitral stenosis. After diagnosis he discharged himself from hospital. Two-and-a-half months later he stopped co-trimoxazole. He stopped tetracycline after 11 months. He was readmitted to hospital 15 months after the initial admission in distinct congestive heart failure. Despite bed rest, digoxin and diuretic treatment, and the restarting of tetracycline and co-trimoxazole, right ventricular failure persisted. The average duration of illness before diagnosis in our patients was much shorter than that recorded by other workers.10 Only one of our patients developed an arterial embolus. None of our patients developed venous thrombosis, nor did they manifest significant hepatocellular damage during the course of their illness.
The diagnosis of chronic Q fever endocarditis is confirmed when antibody titres to both phase 1 and phase 2 antigens are raised. A phase 1 complement fixing antibody titre of greater than 200 is usually regarded as good evidence of chronic Q fever infection.11 All our patients with the possible exception of case 7 had phase 1 antibody titres in excess of this. Antibody to phase 1 antigen does not normally develop during acute Q fever infection.
The management of chronic Q fever endocarditis is still controversial. In 1965, Ormsbee'2 stated that "Q fever endocarditis has been, so far as is known, uniformly fatal". Darrell'3 maintained that the antibiotics of choice, tetracycline and chloramphenicol on their own, never achieved a cure since they are rickettsiostatic rather than rickettsiocidal. The response to treatment using tetracycline, either on its own or in combination with cotrimoxazole, was considered successful in six patients when improvement was noted clinically, haematologically, and by a fall in phase 1 and phase 2 antibody titres. One patient (case 7) has now been on treatment for seven months and has not shown a significant reduction in his Q fever phase 1 or phase 2 antibody titres, though clinically there has been no deterioration in his overall condition. Another patient with a prosthetic valve died from gross congestive heart failure caused by poor left ventricular function diagnosed before Q fever infection.
It has been suggested that after stopping treatment careful follow-up is mandatory to ensure that there is no recurrence of Q fever endocarditis.'0 Three patients have discontinued treatment after an average course of 18 months and have been followed up for on average 22 months. At the time of stopping treatment phase 1 and phase 2 antibody titres were less than 200. During the period of follow-up of the three patients there was no recurrence of Q fever endocarditis as judged clinically, haematologically, and serologically.
For the successful treatment of Q fever endocarditis tetracycline 2 g/day alone or in combination with co-trimoxazole (320 mg trimethoprim and sulphamethoxazole 1600 mg) per day should be given for a prolonged period. Co-trimoxazole therapy alone might be appropriate treatment but this is unproven. Surgery is indicated when significant haemodynamic difficulties occur but is rarely necessary to 
